Akari Therapeutics PLC expected to post a loss of 4 cents a share - Earnings Preview

Akari Therapeutics

07/04/2023 12:24

* Akari Therapeutics PLC  AKTX.OQ   AKTX.O  is expected
to report
results on April 10 (estimated).
    * 
    * ​Refinitiv's mean analyst estimate for Akari Therapeutics
PLC is
for a loss of 4 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "Buy".​
    * Wall Street's median 12-month price target for Akari
Therapeutics PLC is $2.75​, above​ its last closing price
of $0.21. ​​​

This summary was machine generated April 7 at 11:24 GMT.  All
figures in US dollars  unless otherwise stated